1,666 Shares in Medpace Holdings, Inc. $MEDP Purchased by Fideuram Asset Management Ireland dac

Fideuram Asset Management Ireland dac purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,666 shares of the company’s stock, valued at approximately $936,000.

A number of other institutional investors have also recently bought and sold shares of the business. Operose Advisors LLC acquired a new position in Medpace during the fourth quarter worth approximately $56,000. Rothschild Investment LLC increased its position in Medpace by 30.8% during the fourth quarter. Rothschild Investment LLC now owns 1,224 shares of the company’s stock worth $687,000 after buying an additional 288 shares during the last quarter. Foundations Investment Advisors LLC acquired a new position in Medpace during the fourth quarter worth approximately $472,000. Geode Capital Management LLC increased its position in Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after buying an additional 24,625 shares during the last quarter. Finally, King Luther Capital Management Corp increased its position in Medpace by 4.2% during the fourth quarter. King Luther Capital Management Corp now owns 18,331 shares of the company’s stock worth $10,296,000 after buying an additional 739 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Down 0.2%

Shares of NASDAQ:MEDP opened at $447.11 on Friday. Medpace Holdings, Inc. has a 12-month low of $291.28 and a 12-month high of $628.92. The stock has a market cap of $12.77 billion, a PE ratio of 28.10, a P/E/G ratio of 2.27 and a beta of 1.19. The business has a 50 day moving average of $457.47 and a 200-day moving average of $513.97.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter in the previous year, the company posted $3.67 earnings per share. The business’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Insider Buying and Selling at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 20.50% of the company’s stock.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Bronstein, Gewirtz & Grossman, Faruqi & Faruqi, The Gross Law Firm, Rosen, Schall, Pomerantz, and others, issued updates this week about a pending class-action lawsuit against Medpace and reminded shareholders of upcoming lead-plaintiff deadlines, keeping legal risk in focus for the stock. Article Title
• Neutral Sentiment: The latest notices do not add new operational or financial guidance from Medpace; they mainly reiterate the same securities-fraud allegations and court deadline, so the immediate market impact is likely driven more by headline risk than by fundamentals. Article Title
• Neutral Sentiment: Short-interest data released alongside the legal headlines showed no meaningful borrowable shares reported, suggesting the move in MEDP is being driven by news flow rather than a clear short-selling signal.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Mizuho set a $582.00 price target on Medpace in a research report on Wednesday, February 11th. Leerink Partners lowered their price target on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. BMO Capital Markets lowered their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and lowered their price target for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Finally, Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.